HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Published studies have demonstrated significant synergistic interactions between venetoclax and HDAC inhibitors (vorinostat and romidepsin) in the treatment of CTCL in vitro, which were dose-dependent and showed an antagonistic trend at lower doses and synergy at higher doses.